



FOR IMMEDIATE RELEASE

## **Powder Pharmaceuticals Hong Kong made the first shipment to US**

### ***The First Medical Device Combination Manufacturing Site in HK and Product manufactured for US Market***

Hong Kong, 3<sup>rd</sup> March 2014 – Lee's Pharmaceutical Holdings Limited ("the Group" or "Lee's") (Main Board Stock Code: 0950; Website: [www.leespharm.com](http://www.leespharm.com)) today announced that Powder Pharmaceuticals, Incorporated ("PPI"), an associated company of the Group, has made its first shipment of its flagship product Zingo™ to the United States.

In July 2013, PPI obtained the approval letter from the US FDA that the supplemental new drug application for PPI's Hong Kong manufacturing site of Zingo™ Powder Intradermal Injection system, which transact in U.S. market is approved. After three years of hard work, PPI is finally able to make Zingo™ available to its distribution partner Marathon for launching into the US market, the number one phase first market in the world.

"This is a breakthrough we are all working dilligently to achive. The commercialization of Zingo™ has truned a new page not only for PPI, but also for the Group," said Dr. Benjamin Li, Chief Executive Officer of the Company.

#### **About Zingo™**

Zingo™ is the first needleless, painless powder injection system to be approved for analgesia at an IV/cannula access site. The rapid onset of analgesia in 1-3 minutes provides care givers and patients the opportunity for a pain-free and needle-free access procedure. Zingo™ is approved for use in children over 3 years of age and in adults. Clinical trials have shown a statistical difference in pain scores during needle access procedures when using Zingo™ versus a placebo system.

#### **About Powder Pharmaceuticals, Incorporated ("PPI")**

PPI is a privately held company based in Hong Kong that is developing products that utilize a proprietary needleless, painless, powder delivery technology. Powder Pharmaceuticals intends to supply Zingo™ globally through international business partners. PPI has obtained from the US FDA for approval of the production of Zingo™ in the new Hong Kong manufacturing facility in July 2013.



---

**FOR IMMEDIATE RELEASE**

**About Lee's Pharmaceutical**

**Lee's Pharmaceutical Holdings Limited** is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at [www.leespharm.com](http://www.leespharm.com).

**Safe Harbor Statement**

*The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*